Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
PTGX Stock Chart & Stats
$76.72
-$0.87(-2.26%)
At close: 4:00 PM EST
$76.72
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$33.31 - $93.25
Previous CloseN/A
Volume120.35K
Average Volume (3M)1.48M
Market Cap
$4.77B
Enterprise Value$2.95B
Total Cash (Recent Filing)$570.47M
Total Debt (Recent Filing)$11.28M
Price to Earnings (P/E)107.7
Beta0.52
Next Earnings
Nov 05, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding62,211,320
10 Day Avg. Volume2,255,187
30 Day Avg. Volume1,483,780
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue14.49
Enterprise Value/Gross Profit14.54
Enterprise Value/Ebitda116.19
Forecast
1Y Price Target
$78.89Price Target Upside2.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialRecent biotech acquisitions suggest a 25-50% premium on PTGX's last closing price could be reasonable, indicating potential value in the acquisition.
Financial StabilityPTGX has a strong balance sheet, ending with total cash of $673.0M and a financial runway through at least YE28.
Potential Milestone PaymentsPTGX will be eligible for a $400M payment from Takeda if the company opts out of U.S. co-promotion of rusfertide, with potential milestone payments increasing to $975M.
Bears Say
Acquisition NegotiationsThe negotiation on acquisition price could be impacted by PTGX's collaboration with Takeda on rusfertide for polycythemia vera.
Clinical Study ChallengesDurable clinical remission could be a more important factor than safety, so data from the Ph3 studies should help to establish icotrokinra's clinical profile.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $33.31 and its highest was $93.25 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $4.77B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 14 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.579 by $0.029.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 62,211,320 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.579. Following the earnings report the stock price went down -5.384%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.89 (2.83% Upside)
$78.89 (2.83% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 607.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.6%
Last 30 Days ▲ 23.0%
Last 30 Days ▲ 23.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.33%
12-Months-Change
Fundamentals
Return on Equity
8.61%
Trailing 12-Months
Asset Growth
16.82%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel peptide-based therapeutics for the treatment of various diseases, particularly hematologic malignancies and autoimmune disorders. The company leverages its proprietary technology platform to design and optimize peptide drugs that aim to address unmet medical needs in these therapeutic areas.
PTGX Stock 12 Month Forecast
Average Price Target
$78.89
▲(2.83% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
Akero Therapeutics
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.63% Insiders
15.35% Mutual Funds
0.14% Other Institutional Investors
61.21% Public Companies and
Individual Investors